西班牙RESCLE注册研究中系统性硬化症及皮肤亚型的肝胆受累:特征与生存分析
基于西班牙RESCLE注册截至2015年1月的1572例系统性硬化症患者,118例(7.5%)存在肝胆受累,以原发性胆汁性胆管炎最常见(67例,4.3%)。肝胆受累与弥漫型皮肤亚型风险较低相关,与钙质沉着、左心室舒张功能不全、干燥综合征和抗着丝点抗体频率较高相关;有无肝胆受累者累积生存无差异。
要点
- 系统性硬化症患者肝胆受累患病率为7.5%,原发性胆汁性胆管炎是最主要病因(4.3%)。
- 肝胆受累在弥漫型皮肤亚型中较少见(5.1% vs 24.4%),与钙质沉着、左心室舒张功能不全、干燥综合征及抗着丝点抗体相关。
- 肝胆受累是2.3%患者的死亡原因,但有无肝胆受累者累积生存无差异。
核心结论
- 系统性硬化症中肝胆受累患病率为7.5%,弥漫型皮肤亚型受累最少,原发性胆汁性胆管炎是主要病因。
- 系统性硬化症合并肝胆受累患者具有特定的临床和免疫学特征,但有无肝胆受累者生存相似。
研究设计与样本
- 研究为基于西班牙RESCLE注册的队列分析,截至2015年1月共纳入1572例系统性硬化症患者,记录所有肝胆异常。
- 按皮肤亚型分为弥漫型皮肤系统性硬化症、局限型皮肤系统性硬化症和无皮肤硬化的系统性硬化症三组进行分析。
主要发现
- 1572例中118例(7.5%)存在肝胆受累,原发性胆汁性胆管炎67例(4.3%),自身免疫性肝炎19例(1.2%),抗线粒体抗体阴性原发性胆汁性胆管炎6例(0.4%)。
- 其他病因包括继发性肝病11例(0.7%)、系统性硬化症相关肝胆受累7例(0.4%)、结节性再生性增生3例(0.2%)、肝硬化3例(0.2%)及不明原因肝胆受累2例(0.1%)。
- 多因素分析显示肝胆受累与弥漫型皮肤亚型风险较低相关(5.1% vs 24.4%),与钙质沉着(26% vs 18%)、左心室舒张功能不全(46% vs 27%)、干燥综合征(51% vs 29%)及抗着丝点抗体(73% vs 44%)频率较高相关。
- 在局限型皮肤亚型中,肝胆受累与从系统性硬化症起病至诊断时间较长(10.8 ± 12.5 vs 7.2 ± 9.3年)、干燥综合征(54% vs 33%)及抗着丝点抗体(80% vs 56%)相关。
- 在无皮肤硬化的系统性硬化症中,肝胆受累与干燥综合征(44% vs 19%)相关;在弥漫型皮肤亚型中未发现相关因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the prevalence and causes of hepatobiliary involvement (HBI) in systemic sclerosis (SSc), to investigate the clinical characteristics and prognosis of SSc patients with HBI (SSc-HBI) and without HBI (SSc-non-HBI), and to compare both groups according to the cutaneous SSc subsets. METHODS: In all, 1572 SSc patients were collected in the RESCLE registry up to January 2015, and all hepatobiliary disturbances were recorded. We investigated the HBI-related characteristics and survival from the entire SSc cohort and according to the following cutaneous subsets: diffuse cutaneous SSc (dcSSc), limited cutaneous SSc (lcSSc), and SSc sine scleroderma (ssSSc). RESULTS: Out of 1572, 118 (7.5%) patients had HBI. Primary biliary cholangitis (PBC) was largely the main cause (n = 67, 4.3%), followed by autoimmune hepatitis (n = 19, 1.2%), and anti-mitochondrial negative PBC (n = 6, 0.4%). Other causes of HBI were as follows: secondary liver diseases (n = 11, 0.7%), SSc-related HBI (n = 7, 0.4%), nodular regenerative hyperplasia (n = 3, 0.2%), liver cirrhosis (n = 3, 0.2%), and HBI of unknown origin (n = 2, 0.1%). In multivariate analysis, HBI was independently associated to lesser risk of dcSSc (5.1% vs. 24.4%), and higher frequency of calcinosis (26% vs. 18%), left ventricular diastolic dysfunction (46% vs. 27%), sicca syndrome (51% vs. 29%), and anti-centromere antibodies (ACA, 73% vs. 44%). According to the cutaneous subsets, HBI was associated (1) in lcSSc, to longer time from SSc onset to diagnosis (10.8 ± 12.5 vs. 7.2 ± 9.3 years), sicca syndrome (54% vs. 33%), and ACA (80% vs. 56%); (2) in ssSSc, to sicca syndrome (44% vs. 19%), and (3) in dcSSc, no associations were found. HBI was the cause of death in 2.3% patients but the cumulative survival according to the presence or absence of HBI showed no differences. CONCLUSIONS: HBI prevalence in SSc is 7.5% and dcSSc is the least involved subset. PBC is the main cause of HBI. Patients with SSc-HBI exhibited specific clinical and immunologic profile. Survival is similar for SSc patients with HBI.
引用
- Marí-Alfonso B, Simeón-Aznar CP, Guillén-Del Castillo A, et al. Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry. Semin Arthritis Rheum. 2017. PMID: 29246416. doi:10.1016/j.semarthrit.2017.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。